5-Fluoro-2-(3-methylhexan-3-yl)pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-Fluoro-2-(3-methylhexan-3-yl)pyridine
• 英文别名: 5-fluoro-2-(3-methylhexan-3-yl)pyridine
• 化学式: C₁₂H₁₈FN
• 分子量: 195.28
• InChiKey: MFRVNXQGIAJVTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• METHOD FOR PRODUCING BENZIMIDAZOLE DERIVATIVE
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US20200071295A1

  公开（公告）日：2020-03-05

  The present invention relates to a process to prepare a benzimidazole derivative useful as a medicament, an intermediate for preparing the medicament, and a process to prepare the intermediate.

  本发明涉及一种制备苯并咪唑衍生物的方法，该衍生物可用作药物，用于制备药物的中间体，以及制备中间体的方法。
• Triazole furan compounds as agonists of the APJ receptor
  申请人：AMGEN INC.

  公开号：US10736883B2

  公开（公告）日：2020-08-11

  Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.

  式（I）和式（II）化合物、其药学上可接受的盐、前述任何化合物的立体异构体或其混合物是 APJ 受体的激动剂，可用于治疗心血管疾病和其他疾病。式（I）和式（II）化合物具有如下结构：(I)；(II)。还要求得到中间体(V)。
• Potassium channel modulators
  申请人：Cadent Therapeutics, Inc.

  公开号：US10774064B2

  公开（公告）日：2020-09-15

  Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.

  本发明提供了式 (I) 的新型化合物：及其药学上可接受的盐类，它们可用于治疗各种可受钾通道调节影响的疾病、失调或病症。还提供了包含式（I）新型化合物及其药学上可接受的盐的药物组合物，以及将其用于治疗一种或多种与钾通道相关的疾病、失调或病症的方法。
• Method for producing benzimidazole derivative
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US11242332B2

  公开（公告）日：2022-02-08

  The present invention relates to a process to prepare a benzimidazole derivative useful as a medicament, an intermediate for preparing the medicament, and a process to prepare the intermediate.

  本发明涉及一种制备用作药物的苯并咪唑衍生物的工艺、一种制备该药物的中间体以及一种制备该中间体的工艺。
• Functionalized heterocycles as antiviral agents
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US11198693B2

  公开（公告）日：2021-12-14

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物或其药学上可接受的盐类： 其可抑制乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒 HBV 生命周期的功能，还可用作抗病毒剂。本发明进一步涉及包含上述化合物的药物组合物，用于给受 HBV 感染的患者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者 HBV 感染的方法。